

Original Article

# New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

Janet Schloss<sup>1,2</sup>, Maree Colosimo<sup>1,3</sup>, Luis Vitetta<sup>4,5</sup>

<sup>1</sup>Mater Private Breast Cancer Centre, Mater Hospital, Brisbane, Australia, <sup>2</sup>Office of Research, Endeavour College of Natural Health, University of Technology, Brisbane, Australia, <sup>3</sup>Medical Oncology Group of Australia, Clinical Oncology Society of Australia, Queensland Clinical Oncology Group, Brisbane, Australia, <sup>4</sup>Sydney Medical School, University of Sydney, Sydney 2006, <sup>5</sup>Medlab Clinical, Sydney, Australia

**Corresponding author:** Janet Schloss  
E-mail: [janet.schloss@uqconnect.edu.au](mailto:janet.schloss@uqconnect.edu.au)

Received: September 10, 2015, Accepted: October 21, 2015

## ABSTRACT

**Objective:** Neurological complications such as chemotherapy-induced peripheral neuropathy (CIPN) and neuropathic pain are frequent side effects of neurotoxic chemotherapy agents. An increasing survival rate and frequent administration of adjuvant chemotherapy treatments involving neurotoxic agents makes it imperative that accurate diagnosis, prevention, and treatment of these neurological complications be implemented. **Methods:** A consideration was undertaken of the current options regarding protective and treatment interventions for patients undergoing chemotherapy with neurotoxic chemotherapy agent or experience with CIPN. Current knowledge on the mechanism of action has also been identified. The following databases PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, CINAHL, CNKI, and Google Scholar were searched for relevant article retrieval. **Results:** A range of pharmaceutical, nutraceutical, and herbal medicine treatments were identified that either showed efficacy or had some evidence of efficacy. Duloxetine was the most effective pharmaceutical agent for the treatment of CIPN.

Vitamin E demonstrated potential for the prevention of cisplatin-IPN. Intravenous glutathione for oxaliplatin, Vitamin B6 for both oxaliplatin and cisplatin, and omega 3 fatty acids for paclitaxel have shown protection for CIPN. Acetyl-L-carnitine may provide some relief as a treatment option. Acupuncture may be of benefit for some patients and Goshajinki-gan may be of benefit for protection from adverse effects of oxaliplatin induced peripheral neuropathy. **Conclusions:** Clinicians and researchers acknowledge that there are numerous challenges involved in understanding, preventing, and treating peripheral neuropathy caused by chemotherapeutic agents. New insights into mechanisms of action from chemotherapy agents may facilitate the development of novel preventative and treatment options, thereby enabling medical staff to better support patients by reducing this debilitating side effect.

**Key words:** Bortezomib, chemotherapy-induced peripheral neuropathy, cisplatin, management, neuropathic pain, prevention, taxane, treatment, vincristine

## Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-limiting side effect resulting from the

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**For reprints contact:** [reprints@medknow.com](mailto:reprints@medknow.com)

**Cite this article as:** Schloss J, Colosimo M, Vitetta L. New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy. *Asia Pac J Oncol Nurs* 2016;3:73-85.

| Access this article online   |  |
|--|--|
| <b>Quick Response Code:</b><br> | <b>Website:</b> <a href="http://www.apjon.org">www.apjon.org</a> |
|  | <b>DOI:</b><br>10.4103/2347-5625.170977                          |

administration of commonly used neurotoxic chemotherapy agents. It is characterized by paresthesia, dysesthesia, impaired movement, and occasionally pain. The most common symptoms reported by patients include sensory symptoms of numbness and tingling, followed by burning, shooting, throbbing, and stabbing feelings. Moreover, patients may experience motor symptoms such as dropping items, splaying fingers, and inability to complete normal daily activities.<sup>[1]</sup> This side effect is difficult to prevent and control without resorting to dose reduction or cessation of chemotherapy treatment.<sup>[2]</sup>

Overall, CIPN is considered a serious and significant neurological adverse effect of chemotherapy and must be monitored from presentation as worsening symptoms can occur from the administered treatment. CIPN may be temporary but in a third of cases, it has been found to be a permanent side effect from the chemotherapy treatment employed.<sup>[3]</sup> There have been numerous studies trialing pharmaceutical agents, nutrients, herbs, and other modalities for the prevention and/or treatment of CIPN. Thus, the objective was to identify the best possible evidence-based options for clinicians that could be of beneficial assistance to patients undergoing chemotherapeutic treatments.

## Methods

The aim of this inquiry was to investigate which efficacious protective and/or treatment options were available for patients undergoing chemotherapy with a neurotoxic chemotherapeutic agent or who experience CIPN. New insights into mechanisms of action from chemotherapeutic agents may highlight new preventative and treatments options that could assist medical staff provide patients with treatment options that could decrease the debilitating burden encountered with the side effects of CIPN. A mini-literature review was conducted for each section.

### Selection criteria

The inclusion criteria for each sub-section included:

1. Any type of human clinical trial (e.g., randomized controlled trial [RCT]) or descriptive study, e.g., retrospective studies, case-control studies).
2. Animal studies.
3. The use of a mechanism of action study that administered a pharmaceutical, nutrient(s) or herbal medicine as the main intervention and specifically investigating its effects on reducing the primary outcome, i.e., CIPN, and
4. The journal article or abstract was in English.

### Databases

The following databases were used to retrieve journal articles: PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, and Google Scholar. Chinese Databases included CNKI and CINAHL.

### Search terms

Electronic databases were searched using the following search terms, “CIPN” or “cisplatin” or “taxanes” or “paclitaxel” or “docetaxel” or “oxaliplatin” or “carboplatin” or “platinum compounds” or “proteasome inhibitors” and “peripheral neuropathy” or “CIPN” and “mechanism of action” or “pharmaceutical agent” or “nutrient” or “herb” or “herbal medicines” or “chinese herbal medicines” or “ayurvedic herbal medicines.”

### Risk bias assessment

The risk bias of both animal and human studies was assessed using the Cochrane risk of bias assessment tool (<http://handbook.cochrane.org/>, part 2, Chapter 8).

### Data synthesis

All human clinical trial data (excluding descriptive studies) was analyzed using RevMan version 5.2.7 (Cochrane Informatics and Knowledge Management Department) to quantify and compare the efficacy outcomes of intervention versus control.

## Results

### Mechanisms of action for chemotherapy-induced peripheral neuropathy

The administration of chemotherapeutic agents results in numerous cellular changes including loss of sensory terminals in the skin, alterations of membrane receptors, changes in intracellular signaling, neurotransmissions, excitability, and cellular metabolism. These effects can negatively influence neuronal and glial cell phenotypes which may contribute to the development of CIPN, thus hindering the understanding of specific mechanism underlying this side effect.<sup>[4]</sup> A recent review by Boyette-Davis *et al.*<sup>[4]</sup> identified a number of different mechanisms of actions for CIPN [Table 1].

Insight into the mechanisms of action of chemotherapy agents that contribute to CIPN is important when considering agents that may assist in CIPN prevention and treatment. Although research has provided an understanding of the possible mechanisms underlying CIPN, current clinical trials have not reported effective preventative or treatment options. It is also important

**Table 1: Mechanisms of action identified for CIPN**

| Mechanism of action   | Explanation  | Conclusion   |
|---|--|--|
| Genetic influences  | Recent review identified a number of studies looking at CIPN genetics <sup>[5]</sup> however, these results have not been reproducible <sup>[4]</sup>  | Potential to identify patients at increased risk of CIPN. Further research still required  |
| Neuronal influences   |  |  |
| Altered activity and expression of voltage-gated ion channels | Na <sup>+</sup> entry into a neuron is altered e.g., oxalate from oxaliplatin, leading to altered thresholds and ectopic firing. <sup>[6,7]</sup> ↑ Na <sup>+</sup> ↓ K <sup>+</sup> Ca <sup>++</sup> also plays a major role with increased levels of voltage-gated Ca <sup>++</sup> channel mRNA reported in DRG <sup>[8]</sup>  | Possible protection by use of voltage-gated K <sup>+</sup> channel openers e.g. retigabine (mouse study). <sup>[9]</sup> Administration of voltage-gated Ca <sup>++</sup> drugs such as gabapentin and ethosuximide may decrease reflex hypersensitivity <sup>[10,11]</sup>  |
| Alterations of neurotransmission                              | Altered serotonin transporters <sup>[12]</sup><br>Altered glutamate signaling <sup>[13]</sup><br>↓ expression of glutamate transporter GLAST in spinal astrocytes <sup>[14,15]</sup><br>Animal models show ↓ spinal mu-opioid receptor activation by endomorphin-1 <sup>[16]</sup><br>Altered endocannabinoids <sup>[17]</sup><br>Possible alterations of A3 adenosine receptors <sup>[18]</sup>   | ↑ clearance of excitatory neurotransmitter glutamate prevents excitotoxicity which may affect CIPN <sup>[19]</sup><br>Down regulation of glutamate transporters maybe a common mechanism in CIPN subtypes <sup>[4]</sup>   |
| Alterations of transient receptor potential channels          | ↑ TRPV1 expression found in DRG in animal models affecting thermal hypersensitivity <sup>[20]</sup><br>Cold sensitivity from oxaliplatin was found to be TRPA1 dependent in animal models <sup>[21]</sup><br>Possible modulation of TRPM8 channel may have analgesic effects <sup>[22]</sup>   | TRPA1 was found to activate cold sensitivity in rodents but has not been able to be replicated in humans <sup>[23]</sup> limiting translational impact<br>Possible involvement with TRPV1, TRPV4 and TRPA1 channels after chemotherapy <sup>[24]</sup><br>Topical menthol has been reported for carboplatin-IPN <sup>[25]</sup>  |
| Intracellular signaling pathways                              | Caspase signaling associated with animal models causing potential neuron apoptosis <sup>[26]</sup><br>Erk 1/2 and p38 MAPK are activated by cisplatin and oxaliplatin leading to DRG apoptosis <sup>[27]</sup>   | Targeting caspases may assist in protecting against CIPN development<br>Possible protection by promoting NGF <sup>[28]</sup>   |
| Changes to intracellular structures                           | Damage to glial and neuronal mitochondria has been a focus <sup>[29]</sup><br>↓ expression of APE1 is associated with ↑ nociceptive responding <sup>[30]</sup><br>Other organelles damaged include lysosomes and endoplasmic reticulum in neurons and schwann cells <sup>[31]</sup><br>↓ axonal transport from paclitaxol and vincristine due to anti-tubulin activity <sup>[32,33]</sup> plus bortezomib and oxaliplatin <sup>[34,35]</sup> | APE1 may have a potential protective effect but still needs further research <sup>[30]</sup><br>Further research into ↓ axonal transport may prove to have potential protective properties   |
| Loss of IENF and MC   | Reason for ↓ touch perception <sup>[36]</sup><br>Specific mechanism of loss of IENF is unclear <sup>[4]</sup><br>↓ CCL2, a chemokine involved in proinflammatory responses in DRG linked with CIPN <sup>[37]</sup>   | Tetracycline derivative, minocycline, prevents IENF loss by reducing neuro-inflammation. In animal models is has shown to be protective for oxaliplatin and palitaxel CIPN <sup>[38,39]</sup><br>Interventions to suppress CCL2 has been found to block behavioral signs of CIPN and distal IENF density in rats <sup>[37]</sup> |
| Glial cell function   | Chemotherapy causes cytokine release e.g., TNF-α from schwann, satellite, and astrocyte cells resulting in decreased nerve fibers impairing action potential, DRG neuron apoptosis, and neuropathic pain <sup>[40-45]</sup><br>Satellite cells affected by chemotherapy also causes increased gap junction coupling causing an analgesic response in mice <sup>[46]</sup>  | Treatment with minocycline or carbenoxolone can decrease hyperalgesia response in rodents <sup>[14]</sup>  |
| Cytokine and chemokine binding                                | Chemotherapeutics enhances cytokine release e.g., TNF-α, IL-1β and chemokine e.g., MCP-1 bind to receptors located on neurons and glial cells and increase pain <sup>[47]</sup><br>TLR is one receptor known to be involved with CIPN <sup>[48]</sup><br>In rats, TLR4 increases palitaxol-induced hyperalgesia<br>MCP-1 receptor CCR2 is altered in CIPN <sup>[37]</sup>  | TLR4 antagonists e.g. a lipopolysaccharides isolated from <i>Rhodobacter sphaeroides</i> has been found to decrease hyperalgesia in rats <sup>[49]</sup><br>TLR2 antagonists have also been found to assist cisplatin CIPN <sup>[50]</sup><br>CCR2 antagonists decrease neuropathic pain in mice <sup>[51]</sup>                 |

CIPN: Chemotherapy-induced peripheral neuropathy, DRG: Dorsal root ganglia, TRPV1: Transient receptor potential vanilloid 1, TRPM8: Transient receptor potential melastatin 8, TRPA1: Transient receptor potential ankyrin 1, MAPK: Mitogen-activated protein kinase, NGF: Nerve growth factor, IENF: Intraepidermal nerve fibers, MC: Meissner's corpuscle, TNF-α: Tumor necrosis factor alpha, IL-1β: Interleukin 1, beta, MCP-1: Monocyte chemoattractant protein-1, TLR: Toll-like receptors, GLAST: Glutamate-aspartate transporter, APE1: Apurinic/apyrimidinic endonuclease 1

when studying the mechanisms of action underlying CIPN development, the validity and reliability of the reported results. From the data identified to date, further research and treatment options are warranted and a redirected focus may be needed that examines the role of glial cells and inflammatory pathways in CIPN.

### Current treatment and prevention options

Clinical trials investigating pharmaceutical agents and complementary and alternative therapies for the

prevention and treatment CIPN were identified. Listed below are the current trials for each agent categorized under individual neurotoxic chemotherapy agent. Due to the comprehensive data acquisition in each category, studies of different levels of evidence have been included in this analysis. The studies included were evaluated using a separate tool, the Australian National Health and Medical Research Council's (NHMRC) body of clinical evidence assessment matrix. This is an assessment tool that assigns a level/grade (Level I: Strongest evidence to

**Table 2: Pharmaceutical agents trialed for CIPN**

| Chemotherapy agent          | Pharmaceutical agents trialed                  | Level of evidence | Total number of participants from trials | Recommendations   |
|-----------------------------|--|-------------------|--|---|
| Cisplatin                   | Amifostine <sup>[58-64]</sup>                  | Level III         | 657                                      | Possible ototoxicity protection particularly for children   |
| Limited protection for CIPN |  |                   |  |   |
| Oxaliplatin                 | Amifostine <sup>[65]</sup>                     | Level IIIc        | 15                                       | Possible decrease in severity of CIPN by subcutaneous application   |
|                             | Carbamazepine/oxcarbazepine <sup>[66-69]</sup> | Level IIIb        | 103                                      | Limited protection noted  |
|                             | Calcium channel blockers <sup>[70]</sup>       | Level IIIb        | 116                                      | Retrospective study found they lowered the incidence for acute CIPN but not chronic                           |
| Taxanes                     | Amifostine <sup>[61,71,72]</sup>               | Level III         | 98                                       | Possible protection against severe CIPN development   |
| Vincristine                 | Amifostine <sup>[64]</sup>                     | Level IIIa        | 97                                       | No protection noted   |
| Carboplatin/taxane          | Amifostine <sup>[73-77]</sup>                  | Level III         | 446                                      | Possible protection against severe CIPN development   |
|                             | rhuLIF <sup>[78]</sup>                         | Level II          | 117                                      | No protection noted   |
| CIPN treatment              | Gabapentin <sup>[79,80]</sup>                  | Level II          | 177                                      | Failed to show any benefit although may decrease pain in some people  |
|                             | Lamotrigine <sup>[81]</sup>                    | Level II          | 131                                      | No benefit noted  |
|                             | Pregabalin <sup>[57]</sup>                     | Level IIIb        | 23                                       | May decrease the severity of sensory oxaliplatin PN in patients who reach the target dose of 150 mg tds (22%) |
|                             | Amitriptyline/nortriptyline <sup>[82,83]</sup> | Level III         | 95                                       | Modest effect on reducing pain  |
|                             | Venlafaxine <sup>[54-56]</sup>                 | Level IV          | 4  | Possible effect on reducing pain although only case studies   |
|                             | Duloxetine <sup>[52,53]</sup>                  | Level II          | 232                                      | Statistically significant in reducing pain from CIPN  |

CIPN: Chemotherapy-induced peripheral neuropathy, PN: Peripheral neuropathy

level IV: Weakest evidence) based on the strength of the published study.<sup>1</sup>

### Pharmaceutical agents

No pharmaceutical agent has yet been reported to significantly prevent CIPN. Several agents have been found to have a moderate benefit for the treatment of CIPN however, further trials are required. Possible beneficial treatment options for pain associated with CIPN include duloxetine (Cymbalta)<sup>[52,53]</sup> and other anti-depressants such as venlafaxine (Effexor).<sup>[54-56]</sup> Currently, pregabalin (Lyrica) has been administered with some benefit for nerve pain although only one open label trial<sup>[57]</sup> has been conducted with CIPN. Table 2 presents the chemotherapeutic agents and the pharmaceutical agents trialed for each drug, the total number of participants in all the trials conducted on the drug and the outcomes reported.

### Nutraceutical agents

Currently, there are no established neuroprotective nutraceuticals or treatment options for CIPN. There are several nutraceuticals which have shown promise for selective neurotoxic chemotherapeutic agents such as Vitamin E with cisplatin,<sup>[84-86]</sup> intravenous glutathione for oxaliplatin administration,<sup>[87,88]</sup> Vitamin B6 with

hexamethylmelamine,<sup>[89]</sup> and cisplatin although it was reported to interfere with treatment response rate and omega 3 fatty acids for paclitaxel.<sup>[90]</sup> Acetyl-L-carnitine has also shown promise as a treatment option for CIPN<sup>[91,92]</sup> with further research required from large RCTs. Overall, the results with the administration of various nutraceuticals remains inconsistent and further investigations are required to confirm efficacy and safety. Table 3 presents the trials conducted on nutraceuticals with specific chemotherapeutic agents.

### Herbal medicines

A number of herbal medicines have shown promise as treatment and preventative agents for CIPN. However, the majority of the journal articles identified were laboratory animal studies ( $n = 17$ ). Human studies consisted of one multi-center, randomized double-blind placebo-controlled trial, six randomized trials, six retrospective studies, one uncontrolled study, and three case reports [Table 4]. From the Asian herbal combinations, Gosha-jinki-gan (GJG) is the herbal medicine that has been trialed extensively in animal studies and human clinical trials.<sup>[120-122,128,129,132-135]</sup> There are three retrospective studies used controls for FOLFOX (oxaliplatin, fluorouracil, and leucovorin) and paclitaxel administration,<sup>[120,121,128]</sup> one RCT<sup>[134]</sup> comparing Vitamin B12 administration with the herbal combination and a recent Phase II multi-center, randomized, double-blind, placebo-controlled trial conducted as an adjuvant treatment with FOLFOX.<sup>[129]</sup> All studies concluded that

<sup>1</sup>National Health and Medical Research Council. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. Commonwealth of Australia: National Health and Medical Research Council 2009.



**Table 3: Nutraceuticals agents trialled for CIPN**

| Chemotherapy agent | Nutraceutical trialled                             | Level of evidence             | Total number of participants from trials | Recommendations  |
|--------------------|--|-------------------------------|--|--|
| Cisplatin          | Vitamin E <sup>[84,86,93]</sup>                    | Level II                      | 190                                      | Recommended as an adjunct during treatment to prevent CIPN. Dose: 400 mg/day   |
|                    | Glutamine <sup>[94]</sup>                          | Level III                     | 26                                       | Possible recommendation as it may reduce severity of CIPN. Dose: 2 days consequently with cisplatin                                    |
|                    | Alpha-Lipoic acid <sup>[95]</sup>                  | Level II, Level IIIa          | 243                                      | Not recommended as no protection noted   |
|                    | Glutathione <sup>[96-98]</sup>                     | Level II                      | 244                                      | Trend toward protection. Dose: 1.5-2.5 g daily   |
|                    | Vitamin B6 <sup>[89]</sup>                         | Level IIIb                    | 248                                      | Prevented CIPN but adversely affected response duration. Dose: 300 mg daily  |
| Oxaliplatin        | Magnesium/calcium infusions <sup>[94,99-104]</sup> | Level II                      | 418                                      | Conflicting results but is not recommended to use in conjunction with treatment  |
|                    | Vitamin E <sup>[105]</sup>                         | Level II                      | 34                                       | Not recommended as no differences noted. Dose: 400 mg/day  |
|                    | Alpha-lipoic acid <sup>[95,106]</sup>              | Level III                     | 15                                       | Reduced severity of severe CIPN. Dose: 800 mg daily  |
|                    | N-acetyl cysteine <sup>[107]</sup>                 | Level IIIa                    | 14                                       | Not recommended as no differences noted. Dose: 1200 mg daily   |
|                    | Glutathione <sup>[87,89]</sup>                     | Level II, Level IIIb          | 79                                       | Possible protection as one trial had a significant protective effect. Dose: 1500 mg  |
|                    | Glutamine <sup>[108]</sup>                         | Level IIIa                    | 88                                       | Possible recommendation as it may reduce severity of CIPN. Dose: 15 g twice a day, or IV 20 g for 2 days consequently with oxaliplatin |
|                    | Vitamin B6 <sup>[109]</sup>                        | Level II                      | 23                                       | Recommended, as it may prevent CIPN  |
| Taxanes            | Glutamine <sup>[110,111]</sup>                     | Level IIIa                    | 47                                       | Not recommended as it was not statistically significant Dose: 10 g t.i.d for 4 days after chemotherapy                                 |
|                    | Acetyl-L-carnitine <sup>[112]</sup>                | Level IIIa                    | 409                                      | Not recommended as worsened CIPN in patients taking ALC. Dose: 3000 mg daily   |
|                    | Omega 3 fatty acids <sup>[91]</sup>                | Level IIIa                    | 69                                       | Recommended as it showed statistical significance. Dose: 640 mg t.i.d  |
|                    | Vitamin B12 <sup>[113]</sup>                       | Level IIIb                    | 1  | Recommended as possible protection. A case study from a trial of 71 people. Dose: 1000 mcg daily                                       |
|                    | Cisplatin/taxol                                    | Vitamin E <sup>[99,114]</sup> | Level II                                 | 247  |
| Bortezomib         | Acetyl-L-carnitine <sup>[115]</sup>                | Level II                      | 19                                       | Not recommended to be given prophylactically   |
| CIPN treatment     | Acetyl-L-carnitine <sup>[92,93]</sup>              | Level IV                      | 51                                       | May provide improvement of symptoms if administered after chemotherapy cessation. Dose: 1 g t.i.d                                      |
|                    | Alpha-lipoic acid <sup>[116]</sup>                 | Level III                     | 14                                       | Improved neurological symptoms. Dose 600 mg IV weekly over 3-5 weeks   |

CIPN: Chemotherapy-induced peripheral neuropathy, IV: Intravenous

this herbal combination may provide neuroprotection. Other herbal medicines which showed promise as protective agents include Kieshikajutsubuto<sup>[124]</sup> and Shakuyaku-Kanzo-to<sup>[126]</sup> while sweet bee venom may be useful in treating CIPN once it has developed.<sup>[130,131]</sup>

### Other therapies

Acupuncture has shown promise as a treatment option for CIPN. A systemic review was conducted in 2013 examining the effects of acupuncture on the management of CIPN,<sup>[136]</sup> which identified seven clinical trials and one experimental (rat) study. The limitations identified for these studies included small sample size, poor controls or no controls, poor randomization, and lack of blinding. From this, it can be concluded that while further studies are required, patients with CIPN may benefit from acupuncture.

Another option for clinicians, practitioners, and nurses includes topical application of analgesic agents. A

combination of baclofen 10 mg, amitriptyline HCL 40 mg (3%), and ketamine 20 mg (1.5%) in a base of pluronic lecithin organogel and was found to be beneficial for sensory neuropathy over placebo ( $P = 0.053$ ) and decreased motor neuropathy symptoms ( $P = 0.021$ ).<sup>[137]</sup> However, a Phase III RCT trial on 462 patients with CIPN found no difference in 6 weeks of treatment with 2% ketamine and 4% amitriptyline cream ( $P = 0.363$ ).<sup>[138]</sup> Recent case studies examining the topical application of menthol (1%) have found it beneficial as a novel analgesic therapy for cancer neuropathic pain.<sup>[139]</sup> In addition, high dose topical capsaicin cream may show benefit although no studies for CIPN have been conducted.<sup>[140]</sup>

### Discussion

Despite the incidence of CIPN and the significant impact it has on the effectiveness of chemotherapy due to its dose-limiting effects, there are no current treatment or preventive

**Table 4: Herbal medicines trialled for CIPN**

| Chemotherapy agent | Herbal medicine trialed                             | Level of evidence | Total number of participants from trials | Recommendations  |
|--------------------|---|-------------------|--|--|
| Oxaliplatin        | Ginkgo biloba <sup>[117]</sup>                      | Level IIIb        | 17                                       | Possible neuroprotection, do not use with patients who are on blood thinning medication including aspirin or on avastin/eribitux   |
|                    | Buyang huanwu <sup>[118]</sup>                      | Level II          | 84                                       | Decreased CIPN but information not given. This is a tea that could be drunk through chemotherapy   |
|                    | Geranii herba plus Aconiti radix <sup>[119]</sup>   | Level II          | 58                                       | Was found to decrease neuropathic pain but information not given   |
|                    | GJG <sup>[120,121,122,123]</sup>                    | Level II          | 238                                      | Recommended as it had a positive response. Found to have neuroprotective values. However, only available in Japan and certain Asian countries  |
|                    | Kieshikajutsubuto <sup>[124]</sup>                  | Level III         | 11                                       | Patients had 76.6% improvement. Recommended  |
|                    | Ogikeishigomotsuto <sup>[125]</sup>                 | Level IIIb        | 1  | Decreased neuropathic pain but only a case study. Further research needed  |
| Paclitaxel         | Shakuyaku-kanzo-to <sup>[126]</sup>                 | Level IV          | 44                                       | 50% responded to this while 65% responded to GJG. Both can be recommended in Asian countries   |
|                    | Modified Chai Hu Long Gu Mu Li Wan <sup>[127]</sup> | Level IIIa        | 48                                       | Possible neuroprotection. Worth considering  |
|                    | GJG <sup>[128]</sup>                                | Level IIIa        | 82                                       | Possible neuroprotection and better when administered early. Recommended   |
| Taxol/carboplatin  | Shakuyaku-kanzo-to <sup>[129]</sup>                 | Level III         | 23                                       | Reduced neuropathic pain. Worth trying as a treatment option   |
|                    | Sweet bee venom <sup>[130,131]</sup>                | Level IV          | 16                                       | This is a treatment for CIPN and involves injecting into the acupuncture point. Was found to decrease pain and neuropathy. Requires a qualified and skilled practitioner to administer for treatment |

CIPN: Chemotherapy-induced peripheral neuropathy, GJG: Goshajinkigan

options with conclusive efficacy and safety data. However, there are a number of possible avenues that would be advantageous to trial in a clinical setting or via clinical research. First, the increased ability for genetic testing may provide a new avenue for clinicians to identify individuals at high risk of developing CIPN outside the known risk factors such as diabetes, alcoholism, HIV, and Vitamin B12 deficiencies.<sup>[3]</sup> Considering this side effect can directly affect certain patient's professional ability, general physicality, and quality of life, having the ability to offer this service to patients allows the individual to know their changes of developing this side effect. Hence, certain decisions can then be implemented to assist in possible protection or change chemotherapeutic agents if applicable.

The neuronal influences offer the greatest opportunities for protective and treatment options. First, voltage-gated potassium channel openers such as retigabine<sup>[9]</sup> shows great potential for researchers to conduct a randomized clinical trial to ascertain if this agent does have benefit in preventing CIPN. In addition, the administration of voltage-gated calcium drugs such as gabapentin and ethosuximide may decrease reflex hypersensitivity.<sup>[10,11]</sup> This has the potential as a treatment option for those patients who are experiencing reflex hypersensitivity postchemotherapy.

Alterations of neurotransmitters involving the down regulation of glutamate transporters may have potential

protective benefits. Possible agents that could be considered include phenyl pyrimidine compounds such as the acetylcholinesterase inhibitors used in the treatment of Alzheimer's disease e.g., donepezil, galanathamine, and tacrine.<sup>[141]</sup> These drugs have been shown to protect neuronal cells and decrease glutamate neurotoxicity. This provides a new avenue for researchers to consider for the protection of CIPN.

Another neuronal influence which shows potential for treatment options includes the alterations of transient receptor potential channels. To date, menthol cream has shown promise as a topical treatment for CIPN particularly for carboplatin,<sup>[25]</sup> which works via these channels. This may be an easy option for patients to apply topically to alleviate symptoms of CIPN without further ingestive medicine.

Intracellular signaling activity that involves increasing nerve growth factor (NGF) is another option. Although direct administration of NGF has not shown benefit to date in clinical trials on humans due to unwarranted side effects,<sup>[142]</sup> there are agents that have been found to increase NGF such as Vitamin B12,<sup>[143]</sup> acetyl-L-carnitine,<sup>[144]</sup> rosemary,<sup>[145]</sup> *Polygala tenuifolia* (Ninjin-Yoei-To, Kamp Japanese Herbal),<sup>[146]</sup> *Codonopsis pilosula*,<sup>[147]</sup> and *Dioscorea nipponica*.<sup>[148]</sup> *Dioscorea* in particular has been trialed for diabetic neuropathy and was found to increase neurite

outgrowth, enhance nerve conduction, and exhibit improvement on damaged axons. The fact that it has been found to reverse functional and structural changes and induce neural regeneration may make this herb an excellent candidate for a trial on CIPN.<sup>[148]</sup>

Changes to intracellular structures are another mechanism of action by which there is an opportunity. APE1 may have a potential protective effect by decreasing axonal transport but still needs further research.<sup>[30]</sup> Loss of intraepidermal nerve fibers (IENF) and Meissner's corpuscle also gives rise to opportunities. Currently, tetracycline derivatives have not been clinically trialed on humans for CIPN, but derivatives, such as minocycline, has been found to prevent IENF loss by reducing neuro-inflammation. In animal models, it has shown to be protective for oxaliplatin and paclitaxel CIPN.<sup>[38,39]</sup> This may be an agent that researchers and clinicians could trial considering the positive results found in animal models.

Glial cell function is another mechanism which could be targeted. Again treatment with tetracycline derivatives such as minocycline or carbenoxolone has been found to decrease hyperalgesia response in rodents.<sup>[14]</sup> This may provide another treatment option for clinicians and researchers. Finally, decreasing inflammation could provide protection against CIPN. Nonsteroidal anti-inflammatory agents have not provided a treatment option for people experiencing CIPN as they are not peripherally acting;<sup>[149]</sup> however that opens the field for other agents that could play a protective role.

A number of nutrients and herbal medicines that have shown potential for protective benefits for CIPN possess anti-inflammatory activity. These include omega 3 fatty acids,<sup>[91]</sup> Vitamin E,<sup>[86]</sup> curcumin,<sup>[150]</sup> chamomile,<sup>[151]</sup> sweet bee venom,<sup>[152,153]</sup> and the combination of Asian herbal medicines.<sup>[154-157]</sup> Further investigations in the anti-inflammatory activity and prevention of CIPN are required.

Currently, no pharmaceutical, nutraceutical, or complementary agent has been found beneficial in preventing or treating CIPN. Based on the data collected, various agents may be suggested although the level of evidence of the studies needs to be recognized. Certain pharmaceutical agents have shown potential for the treatment of CIPN pain as with duloxetine (Cymbalta) and other anti-depressants such as venlafaxine (Effexor) although Effexor was case study based. Pregabalin is the pharmaceutical drug of choice for clinicians at present based on an open label trial. This has been

chosen due to lower dose and less side effects compared to gabapentin.

For nutraceuticals, Vitamin E shows potential for prevention of cisplatin-induced ototoxicity, intravenous glutathione for oxaliplatin administration, Vitamin B6 for both oxaliplatin and cisplatin and omega 3 fatty acids for paclitaxel administration. Acetyl-L-carnitine may provide some relief as a treatment option for CIPN after chemotherapy cessation but should not be used as a preventative agent during chemotherapy. Acupuncture may be of benefit for some patients and GJG may be of benefit for protection of oxaliplatin-IPN for patients in Japan. A number of Asian herbs have been found to have possible benefits for treatment and may provide some relief for patients experiencing neuropathic pain from chemotherapy.

The new insights into the mechanism of actions of CIPN may highlight new drugs, nutrients, or herbs that could assist in prevention of this disabling side effect. However currently, there is no gold standard prevention or treatment of CIPN. It is suggested for clinicians, nurses, and other health professionals treating people with CIPN to use composite measurement outcomes including the full complexity of both positive symptoms (pain, paresthesia, and dysesthesia) and negative ones (numbness).<sup>[158]</sup> Trialing potential treatment options such as acetyl-L-carnitine on patients with numbness and dysesthesia might be worthwhile. Discussing, identifying, and suggesting interventions with possible protective benefits for patients such as Vitamin E, B12, and omega 3 fatty acids displays best care.

If these interventions do not prevent this side effect, and as there is still no proven prophylactic or therapeutic intervention, patient presentation of CIPN during chemotherapy requires modification or cessation of treatment. This is still the preferred strategy to date for patients. Ultimately, collaboration of health professionals and implementing strategies to prevent side effects such as CIPN give rise to best care benefits for patients which should be the aim for all healthcare practitioners.

## Conclusion

Clinicians and researchers acknowledge that there are numerous challenges involved in understanding, preventing, and treating peripheral neuropathy caused by chemotherapy agents. New insights into mechanisms of action from these chemotherapeutic agents may facilitate the development of novel preventative and treatment options, thereby enabling medical staff to better support patients by reducing this debilitating side effect.

## Acknowledgments

Endeavor office of research, Dr. Amie Steel for assistance with editing.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## References

- Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, *et al.* Chemotherapy-induced peripheral neurotoxicity: A critical analysis. *CA Cancer J Clin* 2013;63:419-37.
- Smith JA, Benbow SJ. Meeting Report: Inaugural Chemotherapy-Induced Peripheral Neuropathy Symposium — Santa Barbara, CA, February 2015. *Cancer Res* 2015. pii: Canres. 1145.2015.
- Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. *Oncol Nurs Forum* 2005;32:305-11.
- Boyette-Davis JA, Walters ET, Dougherty PM. Mechanisms involved in the development of chemotherapy-induced neuropathy. *Pain Manag* 2015;5:285-96.
- Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. *Lancet Oncol* 2011;12:1151-61.
- Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. *J Neurophysiol* 2001;85:2293-7.
- Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. *Br J Pharmacol* 2005;146:1027-39.
- Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, *et al.* Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. *EMBO Mol Med* 2011;3:266-78.
- Nodera H, Spieker A, Sung M, Rutkove S. Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy. *Neurosci Lett* 2011;505:223-7.
- Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. *Pain* 2004;109:150-61.
- Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: Analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. *Neuroscience* 2007;144:714-20.
- Hansen N, Uçeyler N, Palm F, Zelenka M, Biko L, Lesch KP, *et al.* Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. *Neurosci Lett* 2011;495:93-7.
- Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? *Neurosci Lett* 2015;596:90-107.
- Robinson CR, Dougherty PM. Spinal astrocyte gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy. *Neuroscience* 2015;285:1-10.
- Cata JP, Weng HR, Chen JH, Dougherty PM. Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. *Neuroscience* 2006;138:329-38.
- Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, *et al.* Spinal changes of a newly isolated neuropeptide endomorphin-2 concomitant with vincristine-induced allodynia. *PLoS One* 2014;9:e89583.
- Uhelski ML, Khasabova IA, Simone DA. Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy 2015;113:1501-10.
- Janes K, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, *et al.* A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. *Pain* 2014;155:2560-7.
- Matute C, Domercq M, Sánchez-Gómez MV. Glutamate-mediated glial injury: Mechanisms and clinical importance. *Glia* 2006;53:212-24.
- Hara T, Chiba T, Abe K, Makabe A, Ikeno S, Kawakami K, *et al.* Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion. *Pain* 2013;154:882-9.
- Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N, *et al.* Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. *Pain* 2011;152:1621-31.
- Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, Robertson DC, *et al.* Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. *Curr Biol* 2006;16:1591-605.
- Chen J, Kang D, Xu J, Lake M, Hogan JO, Sun C, *et al.* Species differences and molecular determinant of TRPA1 cold sensitivity. *Nat Commun* 2013;4:2501.
- Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. *Neuroscience* 2011;193:440-51.
- Storey DJ, Colvin LA, Mackean MJ, Mitchell R, Fleetwood-Walker SM, Fallon MT. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery. *J Pain Symptom Manage* 2010;39:e2-4.
- Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol induces caspase-10-dependent apoptosis. *J Biol Chem* 2004;279:51057-67.
- Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. *J Pain* 2009;10:534-41.
- Scuteri A, Galimberti A, Ravasi M, Pasini S, Donzelli E, Cavaletti G, *et al.* NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/SapK and ERK1/2. *Neurosci Lett* 2010;486:141-5.
- Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. *Pain* 2006;122:245-57.



30. Kelley MR, Jiang Y, Guo C, Reed A, Meng H, Vasko MR. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. *PLoS One* 2014;9:e106485.
31. Shin YK, Jang SY, Lee HK, Jung J, Suh DJ, Seo SY, *et al.* Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy. *Glia* 2010;58:1961-76.
32. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. *J Clin Oncol* 2006;24:1633-42.
33. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy. *Neurotoxicology* 2013;37:231-9.
34. Staff NP, Podratz JL, Grassner L, Bader M, Paz J, Knight AM, *et al.* Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. *Neurotoxicology* 2013;39:124-31.
35. Schellingerhout D, LeRoux LG, Hobbs BP, Bredow S. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. *PLoS One* 2012;7:e45776.
36. Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, Kennedy WR, *et al.* Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. *J Pain* 2011;12:1017-24.
37. Zhang H, Boyette-Davis JA, Kosturakis AK, Li Y, Yoon SY, Walters ET, *et al.* Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. *J Pain* 2013;14:1031-44.
38. Boyette-Davis J, Xin W, Zhang H, Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. *Pain* 2011;152:308-13.
39. Boyette-Davis J, Dougherty PM. Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. *Exp Neurol* 2011;229:353-7.
40. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. *Minerva Anestesiol* 2006;72:151-69.
41. Cavaletti G, Cavalletti E, Oggioni N, Sottani C, Minoia C, D'Incalci M, *et al.* Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. *Neurotoxicology* 2000;21:389-93.
42. Oztürk G, Erdogan E, Anlar O, Kösem M, Taspınar M. Effect of leukemia inhibitory factor in experimental cisplatin neuropathy in mice. *Cytokine* 2005;29:31-41.
43. Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, *et al.* Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. *Ann Neurol* 1998;43:46-55.
44. Takeda M, Tanimoto T, Kadoi J, Nasu M, Takahashi M, Kitagawa J, *et al.* Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation. *Pain* 2007;129:155-66.
45. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, *et al.* JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. *J Neurosci* 2009;29:4096-108.
46. Warwick RA, Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. *Eur J Pain* 2013;17:571-80.
47. Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, *et al.* Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. *Brain Behav Immun* 2007;21:686-98.
48. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. *Eur J Immunol* 2001;31:2448-57.
49. Li Y, Zhang H, Zhang H, Kosturakis AK, Jawad AB, Dougherty PM. Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. *J Pain* 2014;15:712-25.
50. Park HJ, Stokes JA, Corr M, Yaksh TL. Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice. *Cancer Chemother Pharmacol* 2014;73:25-34.
51. Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, *et al.* Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. *Proc Natl Acad Sci U S A* 2003;100:7947-52.
52. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, *et al.* Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. *JAMA* 2013;309:1359-67.
53. Takenaka M, Iida H, Matsumoto S, Yamaguchi S, Yoshimura N, Miyamoto M. Successful treatment by adding duloxetine to pregabalin for peripheral neuropathy induced by paclitaxel. *Am J Hosp Palliat Care* 2013;30:734-6.
54. Durand JP, Goldwasser F. Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. *Anticancer Drugs* 2002;13:777-80.
55. Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. *Anticancer Drugs* 2005;16:587-91.
56. Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. *Anticancer Drugs* 2003;14:423-5.
57. Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. *Anticancer Res* 2010;30:2927-33.
58. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. *Cancer* 1988;61:2192-5.
59. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, *et al.* Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. *J Clin Oncol* 1996;14:2101-12.
60. Planting AS, Catimel G, de Mulder PH, de Graeff A, Höppener F, Verweij J, *et al.* Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. *Ann Oncol* 1999;10:693-700.
61. Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, *et al.* Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. *J Clin Oncol* 2003;21:4207-13.
62. Rubin JS, Wadler S, Beitler JJ, Haynes H, Rozenblit A, McGill F, *et al.* Audiological findings in a Phase I protocol

- investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. *J Laryngol Otol* 1995;109:744-7.
63. Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschitl HE, *et al.* A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: An Eastern Cooperative Oncology Group Study (E8188). *Cancer* 2001;92:2517-22.
  64. Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, *et al.* Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. *J Clin Oncol* 2008;26:3749-55.
  65. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: A promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. *Ann Oncol* 2001;12:421-2.
  66. Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. *Dtsch Med Wochenschr* 2002;127:78-82.
  67. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. *J Clin Oncol* 2002;20:1767-74.
  68. Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, *et al.* Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. *Neurology* 2006;67:2253-5.
  69. von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, *et al.* Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. *Invest New Drugs* 2007;25:173-80.
  70. Tatsushima Y, Egashira N, Narishige Y, Fukui S, Kawashiri T, Yamauchi Y, *et al.* Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: A retrospective study of 69 male patients receiving modified FOLFOX6 therapy. *Biomed Pharmacother* 2013;67:39-42.
  71. Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, *et al.* Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: Lack of neuroprotective effect of amifostine. *Clin Cancer Res* 2004;10:461-7.
  72. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, *et al.* Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. *J Clin Oncol* 1999;17:3038-47.
  73. Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, *et al.* Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy — A double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. *Support Care Cancer* 2005;13:797-805.
  74. Lorusso D, Ferrandina G, Gregg S, Gadducci A, Pignata S, Tateo S, *et al.* Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. *Ann Oncol* 2003;14:1086-93.
  75. Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, *et al.* Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. *J Clin Oncol* 2003;21:1767-74.
  76. De Vos FY, Bos AM, Schaapveld M, de Swart CA, de Graaf H, van der Zee AG, *et al.* A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. *Gynecol Oncol* 2005;97:60-7.
  77. Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, *et al.* Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: A single center randomized study. *Med Oncol* 2003;20:237-45.
  78. Davis ID, Kiers L, MacGregor L, Quinn M, Arezzo J, Green M, *et al.* A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. *Clin Cancer Res* 2005;11:1890-8.
  79. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, *et al.* Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). *Cancer* 2007;110:2110-8.
  80. Ross JR, Goller K, Hardy J, Riley J, Broadley K, A'hern R, *et al.* Gabapentin is effective in the treatment of cancer-related neuropathic pain: A prospective, open-label study. *J Palliat Med* 2005;8:1118-26.
  81. Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, *et al.* Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled trial, N01C3. *Cancer* 2008;112:2802-8.
  82. Kautio AL, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. *J Pain Symptom Manage* 2008;35:31-9.
  83. Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, *et al.* Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. *Pain* 2002;98:195-203.
  84. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, *et al.* Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. *J Clin Oncol* 2003;21:927-31.
  85. Pace A, Giannarelli D, Galìè E, Savarese A, Carpano S, Della Giulia M, *et al.* Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial. *Neurology* 2010;74:762-6.
  86. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, *et al.* Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. *Neurology* 2005;64:26-31.
  87. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, *et al.* Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2002;20:3478-83.
  88. Milla P, Airolidi M, Weber G, Drescher A, Jaehde U, Cattel L. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: Effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. *Anticancer Drugs* 2009;20:396-402.
  89. Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, *et al.* Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: A study of the Eastern Cooperative Oncology Group. *Cancer Invest* 1992;10:1-9.
  90. Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, *et al.* Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized

- double-blind placebo controlled trial. *BMC Cancer* 2012; 12:355.
91. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, *et al.* Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. *Eur J Cancer* 2005;41:1746-50.
  92. Maestri A, DePasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. *Tumori* 2005;91:135-8.
  93. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, *et al.* Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. *Neurology* 2005;64:26-31.
  94. Huang JS, Wu CL, Fan CW, Chen WH, Yeh KY, Chang PH. Intravenous glutamine appears to reduce the severity of symptomatic platinum-induced neuropathy: A prospective randomized study. *J Chemother* 2015;27:235-40.
  95. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, *et al.* Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial. *Support Care Cancer* 2014;22: 1223-31.
  96. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. *J Clin Oncol* 1995;13:26-32.
  97. Colombo N, Bini S, Miceli D, Bogliun G, Marzorati L, Cavaletti G, *et al.* Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma. *Int J Gynecol Cancer* 1995;5: 81-86.
  98. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, *et al.* Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial. *Ann Oncol* 1997;8:569-73.
  99. Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, *et al.* Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. *Clin Cancer Res* 2004;10:4055-61.
  100. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. *J Clin Oncol* 2007;25:4028-9.
  101. Muto O, Ando H, Ono T, Itagaki H, Kobayashi Y, Onuki M, *et al.* Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions. *Gan To Kagaku Ryoho* 2007;34:579-81.
  102. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. *Int J Clin Oncol* 2010;15:82-7.
  103. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, *et al.* Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). *J Clin Oncol* 2014;32:997-1005.
  104. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, *et al.* Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. *J Clin Oncol* 2011;29:421-7.
  105. Afonseca SO, Cruz FM, Cubero Dde I, Lera AT, Schindler F, Okawara M, *et al.* Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial. *Sao Paulo Med J* 2013;131:35-8.
  106. Gedlicka C, Scheithauer W, Schüll B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. *J Clin Oncol* 2002;20:3359-61.
  107. Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, *et al.* N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: Preliminary data. *Support Care Cancer* 2006;14: 484-7.
  108. Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, *et al.* Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. *Oncologist* 2007;12:312-9.
  109. Coriat R, Alexandre J, Nicco C, Quinquis L, Benoit E, Chéreau C, *et al.* Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. *J Clin Invest* 2014;124:262-72.
  110. Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, *et al.* Reduction of paclitaxel-induced peripheral neuropathy with glutamine. *Clin Cancer Res* 2001;7:1192-7.
  111. Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. *Clin Oncol (R Coll Radiol)* 2005;17:271-6.
  112. Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, *et al.* Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. *J Clin Oncol* 2013;31:2627-33.
  113. Schloss JM, Colosimo M, Airey C, Vitetta L. Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. *Support Care Cancer* 2015;23:1843-50.
  114. Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, *et al.* The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial. *Support Care Cancer* 2011;19:1769-77.
  115. Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, *et al.* Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: A study from the Wisconsin Oncology Network. *Cancer Chemother Pharmacol* 2014;74:875-82.
  116. Gedlicka C, Kornek GV, Schmid K, Scheithauer W. Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. *Ann Oncol* 2003;14:339-40.
  117. Marshall J, Zakari A, Hwang JJ, Papadopoulos V, Rosenberg A, Silver C. *Ginkgo Biloba* (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy. American Society of Clinical Oncologists Annual Meeting Proceedings. *J Clin Oncol* 2004;22:3670.
  118. Sun YY, Jia YJ, Huang MN, Chen J. Buyang huanwu decoction in prevention of peripheral neuropathy after chemotherapy: A clinical observation. *Guangming J Chin Med* 2008;23: 958-9.
  119. Sima L, Pan L. Influence of Chinese herb on chemotherapy-induced peripheral neuropathy. *Ann Oncol* 2009;20:iii45-6.



120. Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, *et al.* Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. *Evid Based Complement Alternat Med* 2011;2011:418481.
121. Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, *et al.* The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. *Int J Clin Oncol* 2011;16:322-7.
122. Shindo Y, Tenma K, Imano H, Hibino M, Yoshino K, Nakamura M. Reduction of oxaliplatin-related neurotoxicity by Goshajinkigan. *Gan To Kagaku Ryoho* 2008;35:863-5.
123. Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, *et al.* Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): A phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. *Cancer Chemother Pharmacol* 2013;72:1283-90.
124. Yamada T, Kan H, Matsumoto S, Koizumi M, Sasaki J, Tani A, *et al.* Reduction in oxaliplatin-related neurotoxicity by the administration of Keishikajutsu (TJ-18) and powdered processed aconite root. *Gan To Kagaku Ryoho* 2012;39:1687-91.
125. Tatsumi T, Kishi D, Kogure T. The efficacy of ogikeishigomotsuto on chronic cumulative sensory neuropathy induced by oxaliplatin — Case report and literature view. *J Tradit Med* 2009;26:136-40.
126. Hosokawa A, Ogawa K, Ando T, Suzuki N, Ueda A, Kajiura S, *et al.* Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: A multicenter retrospective study. *Anticancer Res* 2012;32:2545-50.
127. Pan L, Gao H, Xing XR. Combined application of traditional Chinese medicine prevention of taxol chemotherapy-induced peripheral neuropathy; A clinical observation. *Inner Mongol J Traditional Chin Med* 2012;3:28.
128. Yamamoto T, Murai T, Ueda M, Katsuura M, Oishi M, Miwa Y, *et al.* Clinical features of paclitaxel-induced peripheral neuropathy and role of Gosya-jinki-gan. *Gan To Kagaku Ryoho* 2009;36:89-92.
129. Fujii K, Okamoto S, Saitoh K, Sasaki N, Takano M, Tanaka S, *et al.* The efficacy of Shakuyaku-Kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma. *Gan To Kagaku Ryoho* 2004;31:1537-40.
130. Park JW, Jeon JH, Yoon J, Jung TY, Kwon KR, Cho CK, *et al.* Effects of sweet bee venom pharmacopuncture treatment for chemotherapy-induced peripheral neuropathy: A case series. *Integr Cancer Ther* 2012;11:166-71.
131. Yoon J, Jeon JH, Lee YW, Cho CK, Kwon KR, Shin JE, *et al.* Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy. *J Acupunct Meridian Stud* 2012;5:156-65.
132. Hashimoto K, Sakumay Y, Kotani J. Histological study of a paclitaxel-induced peripheral neuropathy model treated with goshajinkigan. *J Osaka Dent Univ* 2004;38:109-12.
133. Hashimoto K, Sakumay Y, Kotani J. Goshajinkigan improves paclitaxel-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. *J Osaka Dent Univ* 2006;40:47-52.
134. Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, *et al.* Objective evaluation of the alleviating effects of goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicentre collaborative study. *Exp Ther Med* 2012;3:60-5.
135. Ushio S, Egashira N, Sada H, Kawashiri T, Shirahama M, Masuguchi K, *et al.* Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. *Eur J Cancer* 2012;48:1407-13.
136. Franconi G, Manni L, Schröder S, Marchetti P, Robinson N. A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. *Evid Based Complement Alternat Med* 2013;2013:516916.
137. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, *et al.* A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. *Support Care Cancer* 2011;19:833-41.
138. Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, *et al.* A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study of 462 cancer survivors. *Support Care Cancer* 2014;22:1807-14.
139. Fallon MT, Storey DJ, Krishan A, Weir CJ, Mitchell R, Fleetwood-Walker SM, *et al.* Cancer treatment-related neuropathic pain: Proof of concept study with menthol — A TRPM8 agonist. *Support Care Cancer* 2015;23:2769-77.
140. Evangelista S. Novel therapeutics in the field of capsaicin and pain. *Expert Rev Clin Pharmacol* 2015;8:373-5.
141. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. *Neuropharmacology* 2006;51:474-86.
142. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. *Expert Opin Drug Saf* 2004;3:535-46.
143. Scalabrino G, Peracchi M. New insights into the pathophysiology of cobalamin deficiency. *Trends Mol Med* 2006;12:247-54.
144. Tagliatalata G, Angelucci L, Ramacci MT, Werrbach-Perez K, Jackson GR, Perez-Polo JR. Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor. *Brain Res Dev Brain Res* 1991;59:221-30.
145. Kosaka K, Yokoi T. Carnosic acid, a component of rosemary (*Rosmarinus officinalis* L.), promotes synthesis of nerve growth factor in T98G human glioblastoma cells. *Biol Pharm Bull* 2003;26:1620-2.
146. Yabe T, Tuchida H, Kiyohara H, Takeda T, Yamada H. Induction of NGF synthesis in astrocytes by onjisaponins of *Polygala tenuifolia*, constituents of kampo (Japanese herbal) medicine, Ninjin-yoei-to. *Phytomedicine* 2003;10:106-14.
147. Liu JH, Bao YM, Song JJ, An LJ. Codonopsis pilosula (Franch) Nannf total alkaloids potentiate neurite outgrowth induced by nerve growth factor in PC12 cells. *Acta Pharmacol Sin* 2003;24:913-7.
148. Kang TH, Moon E, Hong BN, Choi SZ, Son M, Park JH, *et al.* Diosgenin from *Dioscorea nipponica* ameliorates diabetic neuropathy by inducing nerve growth factor. *Biol Pharm Bull* 2011;34:1493-8.
149. Lynch JJ rd, Wade CL, Zhong CM, Mikusa JP, Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. *Pain* 2004;110:56-63.
150. Al Moundhri MS, Al-Salam S, Al Mahrouqee A, Beegam S, Ali BH. The effect of curcumin on oxaliplatin and cisplatin



- neurotoxicity in rats: Some behavioral, biochemical, and histopathological studies. *J Med Toxicol* 2013;9:25-33.
151. Berry M. The chamomiles. *Pharm J* 1995;254:191-3.
152. Kwon KR, Choi S, Cha BC. Component analysis of sweet BV and clinical trial on antibody titer and allergic reactions. *J Korean Pharmacopuncture Inst* 2006;9:79-86.
153. Lee JS, Lee JY, Kwon KR, Lee HC. A study on allergic response between bee venom and sweet bee venom pharmacopuncture. *J Korean Pharmacopuncture Inst* 2006;9:61-77.
154. Howes MJ, Perry NS, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. *Phytother Res* 2003;17:1-18.
155. Muthuraman A, Singh N, Jaggi AS. Protective effect of *Acorus calamus* L. in rat model of vincristine induced painful neuropathy: An evidence of anti-inflammatory and anti-oxidative activity. *Food Chem Toxicol* 2011;49:2557-63.
156. Bahar AM, Andoh T, Ogura K, Hayakawa Y, Saiki I, Kuraishi Y. Herbal medicine goshajinkigan prevents paclitaxel-induced mechanical allodynia without impairing antitumor activity of paclitaxel. *Evid Based Complementary Alternat Med* 2013;2013:849754. doi: 10.1155/2013/849754. Epub 2013 Oct 2.
157. Schröder S, Beckmann K, Franconi G, Meyer-Hamme G, Friedemann T, Greten HJ, *et al.* Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? *Evid Based Complement Alternat Med* 2013;2013:423713.
158. Poupon L, Kerckhove N, Vein J, Lamoine S, Authier N, Busserolles J, *et al.* Minimizing chemotherapy-induced peripheral neuropathy: Preclinical and clinical development of new perspectives. *Expert Opin Drug Saf* 2015;14:1269-82.

